MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Cumberland Pharmaceuticals Net Debt 2011-2025 | CPIX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Cumberland Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.7 M | -12.7 M | -15 M | -26 M | -7.57 M | -6.72 M | 352 K | -30.9 M | -14.8 M | -21.9 M | -39.9 M | -40.9 M | -33.3 M | -65.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 352 K | -65.7 M | -23.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-34 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
193 M | $ 1.69 | -3.13 % | $ 182 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
-1.07 B | $ 3.06 | -6.57 % | $ 1.61 B | Canada |
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
285 M | $ 5.18 | -4.17 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
338 M | $ 11.76 | 2.98 % | $ 602 M | USA |
 |
Evoke Pharma
EVOK
|
-2.96 M | $ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | $ 21.39 | 0.14 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
36.3 M | $ 7.17 | 1.85 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
173 M | $ 46.47 | -1.25 % | $ 1.52 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.73 M | $ 1.55 | -0.64 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
21.1 B | $ 6.83 | -1.37 % | $ 2.49 B | Canada |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
-131 M | $ 4.86 | 0.73 % | $ 640 M | USA |
 |
OrganiGram Holdings
OGI
|
90.7 M | $ 1.82 | -5.36 % | $ 402 M | Canada |
 |
Pacira BioSciences
PCRX
|
317 M | $ 26.71 | 1.6 % | $ 1.24 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
691 K | $ 0.88 | -5.09 % | $ 20.5 M | USA |
 |
Solid Biosciences
SLDB
|
-70.9 M | $ 5.81 | -1.02 % | $ 237 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 3.45 | -3.96 % | $ 4.28 M | USA |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 4.32 | 6.4 % | $ 130 M | USA |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
3.05 B | $ 12.85 | -2.17 % | $ 1.77 B | USA |
 |
ProPhase Labs
PRPH
|
-6.41 M | $ 0.11 | -2.7 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-28.4 M | $ 2.02 | -8.68 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | USA |
 |
Veru
VERU
|
-20.9 M | $ 2.43 | 0.41 % | $ 328 M | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
-521 K | $ 1.4 | 14.75 % | $ 6.04 M | USA |
 |
SCYNEXIS
SCYX
|
-31.1 M | $ 0.64 | -1.21 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
14.4 M | $ 11.41 | -6.09 % | $ 7.05 B | Canada |
 |
TherapeuticsMD
TXMD
|
3.68 M | $ 1.69 | -3.43 % | $ 17.6 M | USA |
 |
Zomedica Corp.
ZOM
|
-10.2 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
16.8 B | $ 11.68 | 0.21 % | $ 14.2 B | USA |